

IA Medicaid Member ID #







DOB

## **FAX Completed Form To** 1.833.404.2392

**Pharmacy Help Desk** 1.800.460.8988

**Prescriber Help Desk** 

## **Request for Prior Authorization MODIFIED FORMULATIONS**

(PLEASE PRINT - ACCURACY IS IMPORTANT)

1.833.587.2012

Provider NPI
Prescriber address  Pharmacy name  Address  Phone  Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.  Pharmacy NPI  Pharmacy fax  NDC  Payment for a non-preferred isomer, prodrug or metabolite will be considered when the following criteria are met: Previous trial with a preferred parent drug of the same chemical entity at a therapeutic dose that resulted in a partial response with a documented intolerance and 2) Previous trial and therapy failure at a therapeutic dose with a preferred drug of a different chemical entity indicated to treat the submitted diagnosis if available. The required trial may be overridden when documented evidence is provided that the use of these preferred agent(s) would be medically contraindicated.
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.  Pharmacy NPI  Pharmacy fax  Payment for a non-preferred isomer, prodrug or metabolite will be considered when the following criteria are met: Previous trial with a preferred parent drug of the same chemical entity at a therapeutic dose that resulted in a partial response with a documented intolerance and 2) Previous trial and therapy failure at a therapeutic dose with a preferred drug of a different chemical entity indicated to treat the submitted diagnosis if available. The required trial may be overridden when documented evidence is provided that the use of these preferred agent(s) would be medically contraindicated.
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned.  Pharmacy NPI Pharmacy fax NDC  Payment for a non-preferred isomer, prodrug or metabolite will be considered when the following criteria are met: 7 Previous trial with a preferred parent drug of the same chemical entity at a therapeutic dose that resulted in a partial response with a documented intolerance and 2) Previous trial and therapy failure at a therapeutic dose with a preferred drug of a different chemical entity indicated to treat the submitted diagnosis if available. The required trial may be overridden when documented evidence is provided that the use of these preferred agent(s) would be medically contraindicated.
Pharmacy NPI Pharmacy fax NDC  Payment for a non-preferred isomer, prodrug or metabolite will be considered when the following criteria are met: 1 Previous trial with a preferred parent drug of the same chemical entity at a therapeutic dose that resulted in a partial response with a documented intolerance and 2) Previous trial and therapy failure at a therapeutic dose with a preferred drug of a different chemical entity indicated to treat the submitted diagnosis if available. The required trial may be overridden when documented evidence is provided that the use of these preferred agent(s) would be medically contraindicated.
Payment for a non-preferred isomer, prodrug or metabolite will be considered when the following criteria are met: 10 Previous trial with a preferred parent drug of the same chemical entity at a therapeutic dose that resulted in a partial response with a documented intolerance and 2) Previous trial and therapy failure at a therapeutic dose with a preferred drug of a different chemical entity indicated to treat the submitted diagnosis if available. The required trial may be overridden when documented evidence is provided that the use of these preferred agent(s) would be medically contraindicated.
Previous trial with a preferred parent drug of the same chemical entity at a therapeutic dose that resulted in a partial response with a documented intolerance and 2) Previous trial and therapy failure at a therapeutic dose with a preferred drug of a different chemical entity indicated to treat the submitted diagnosis if available. The required trial may be overridden when documented evidence is provided that the use of these preferred agent(s) would be medically contraindicated.
Previous trial with a preferred parent drug of the same chemical entity at a therapeutic dose that resulted in a partial response with a documented intolerance and 2) Previous trial and therapy failure at a therapeutic dose with a preferred drug of a different chemical entity indicated to treat the submitted diagnosis if available. The required trial may be overridden when documented evidence is provided that the use of these preferred agent(s) would be medically contraindicated.
☐ Horizant (trial of gabapentin) ☐ Invega / Paliperidone ER (trial of risperidone) ☐ Trilipix (trial of Tricor)
☐ Xopenex HFA / levalbuterol tartrate (trial of albuterol HFA) ☐ Xopenex Nebs / levalbuterol nebs (trial of albuterol nebs)
Payment for a non-preferred alternative delivery system will only be considered for cases in which the use of an alternatic delivery system is medically necessary and there is a previous trial and therapy failure with a preferred alternative delivery system as noted in ( ).  Abilify Discmelt (Abilify soln)
Strength:Dosage Instructions:Quantity:Days Supply:
Diagnosis:
Trial with parent drug product: Drug Name & Dose: Trial dates:
Failure Reason:
Failure Reason: Trial with drug of a different chemical entity: Drug Name & Dose: Trial dates:
Trial with drug of a different chemical entity: Drug Name & Dose: Trial dates:
Trial with drug of a different chemical entity: Drug Name & Dose: Trial dates: Failure Reason:
Trial with drug of a different chemical entity: Drug Name & Dose:
Trial with drug of a different chemical entity: Drug Name & Dose:

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.